Alveolar soft part sarcoma presenting with back pain

Amari T Thompson, Samuel J Ford, Anant Desai, David Gourevitch

DESCRIPTION
A 35-year-old man was referred to the Sarcoma service with a 2-year history of worsening back pain, left-sided radicular pain and a mass on CT scan. In the 6 months following the onset of the back pain, he developed progressive numbness and paraesthesia in the L2 dermatome. This was worse on standing. On clinical examination, power was unaffected but somewhat limited by pain. No ‘red flag’ symptoms were present (table 1). The CT scan demonstrated a large retroperitoneal mass on the left with invasion into the L2 vertebra (figure 1 and 2) and bilateral pulmonary metastases. USS-guided biopsy revealed high grade alveolar soft part sarcoma. He was started on palliative radiotherapy (30 Gy and 10 fractions) and given six cycles of doxorubicin and ifosfamide. Imaging at 8 months postdiagnosis has indicated stable disease.

Table 1 ‘Red flag’ symptoms of back pain

<table>
<thead>
<tr>
<th>Sphincter and gait disturbance</th>
<th>Saddle anaesthesia</th>
<th>Severe or progressive motor loss</th>
</tr>
</thead>
<tbody>
<tr>
<td>Widespread neurological deficit</td>
<td>Age &lt;20 or &gt;55 years</td>
<td>Previous malignancy</td>
</tr>
<tr>
<td>Systemic illness</td>
<td>Human immunodeficiency virus</td>
<td>Weight loss</td>
</tr>
<tr>
<td>Intravenous drug use</td>
<td>Steroid use</td>
<td>Structural deformity</td>
</tr>
<tr>
<td>Non-mechanical pain</td>
<td>Fever</td>
<td>Thoracic pain</td>
</tr>
</tbody>
</table>

Alveolar soft part sarcoma is a very rare condition, believed to account for <1% of all soft tissue tumours. Diagnosis is made by a combination of histology and immunohistochemistry; looking for strong nuclear expression of transcription factor 3. Patients are typically young and present with metastases.

Complete wide surgical excision by a sarcoma surgeon is advised in cases where the disease remains localised. Recurrence following complete excision is rare, but metastases may still occur years later. In patients with localised disease survival rates of 60% at 5 years and 38% at 10 years have been documented. Chemoradiotherapy for metastatic disease has been documented in the literature, with limited success.

Learning points
- This unfortunate case serves to remind us that despite the absence of ‘red flag’ symptoms, clinical suspicion should be raised in the presence of progressively worsening symptoms over a short duration.

Contributors ATT and SJF drafted the article, which was edited for submission by AD. The patient was admitted under and reviewed by DG who suggested submission.

Competing interests None declared.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES


